Prediction and prevention of intrahepatic recurrence of hepatocellular carcinoma

Hepatology Research

Volumn 42, Issue 3, 2012, Pages 226-232

  Izumi, Namiki ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

Author keywords

Acyclic retinoid; CD 133; CK19; Epidermal cell adhesion molecule; Hepatocellular carcinoma; Progenitor cell markers; Vitamin K2

Indexed keywords

BRANCHED CHAIN AMINO ACID; CD133 ANTIGEN; CYTOKERATIN 19; EPITHELIAL CELL ADHESION MOLECULE; FARNOQUINONE; INSULIN; INTERFERON; NUCLEOTIDE DERIVATIVE; RETINOID; RIBAVIRIN; SORAFENIB;

ANTIVIRAL THERAPY; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER RECURRENCE; CHEMOEMBOLIZATION; DIABETES MELLITUS; GENE EXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; INTRAHEPATIC RECURRENCE; LIVER CELL CARCINOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VIRUS REPLICATION;

EID: 84857612620     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00922.x     Document Type: Review

References (61)

1. Kudo M, Izumi N, Kokudo N etal. HCC expert panel of Japan society of hepatology. Dig Dis 2011; 29: 339-64.
2. Poon RT. Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge. Hepatology 2011; 54: 757-9.
3. Villanueva A, Hoshida Y, Toffanin S etal. New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 2010; 16: 4688-94.
4. Murakata A, Tanaka S, Mogushi K etal. Gene expression signature of the gross morphology in hepatocellular carcinoma. Ann Surg 2011; 253: 94-100.
5. Kimura O, Takahashi T, Ishii N etal. Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines. Cancer Sci 2010; 101: 2145-55.
6. Yamashita T, Ji J, Brudhu A etal. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136: 1012-24.
7. Komuta M, Spee B, Vander Borght S etal. Clinicopathological study on cholangiocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 2008; 47: 1544-56.
8. Ziol M, Nault JC, Aout M etal. Intermediate hepatobiliary cells predict an increased risk of hepatocarcinogenesis in patients with hepatitis C virus - related cirrhosis. Gastroenterology 2010; 139: 335-43.
9. Yang XR, Xu Y, Shi GM etal. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res 2008; 14: 3850-9.
10. Zhuang PY, Zhang JB, Zhu XD etal. Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK 19 expression in tumor. Cancer 2008; 112: 2740-8.
11. Uenishi T, Kubo S, Yamamoto T etal. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003; 94: 851-7.
12. Durnez A, Verslype C, Nevens F etal. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006; 49: 138-51.
13. Tsuchiya K, Komuta M, Yasui Y etal. Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation. Oncology 2011; 80: 278-88.
14. Sasaki A, Kamiyama T, Yokoo H etal. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol Res 2010; 24: 537-46.
15. Vasuri F, Golifieri R, Fiorentino M etal. OATP 1B1/1B3 expression in hepatocellular carcinomas treated with orthotopic liver transplantation. Virchows Arch 2011; 459: 141-6.
16. Nakamura Y, Mizuguchi T, Kawamoto M etal. Cluster analysis of indicators of liver functional and preoperative low branched-chain amino acid tyrosine ration indicate a high risk of early recurrence in analysis of 165 hepatocellular carcinoma patients after initial hepatectomy. Surgery 2011; 150: 250-62.
17. Hoshida Y, Villanueva A, Kobayashi M etal. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004.
18. Villanueva A, Hoshida Y, Battiston C etal. Combining clinical, pathology, and gene expression data predict recurrence of hepatocellular carcinoma. Gastroenterology 2011; 140: 1501-12.
19. Teufel A, Marquardt JU, Galle PR. Novel insight in the genetics of HCC recurrence and advances in transcriptomic data integration. J Hepatol 2011 E pub July 23.
20. Amaoka N, Osada S, Kanematsu M etal. Clinicopathological features of hepatocellular carcinoma evaluated by vascular endothelial growth factor expression. J Gastroenterol Hepatol 2007; 22: 2202-7.
21. Toyoda H, Kumada T, Kaneoka Y etal. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol 2008; 49: 223-32.
22. Nobuoka D, Kato Y, Gotohda N etal. Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma. Oncol Rep 2010; 24: 521-8.
23. Yamamoto K, Imamura H, Matsuyama Y etal. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy Ann Surg Oncol 2009; 16: 2795-804.
24. Zhang XF, Lai EC, Kang XY etal. Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and a monitor of recurrence of hepatocellular carcinoma after curative liver resection. Ann Surg Oncol 2011; 18: 2218-23.
25. Beppu T, Sugimoto K, Shiraki K etal. Clinical significance of tumor markers in detection of recurrent hepatocellular carcinoma after radiofrequency ablation. Int J Mol Med 2010; 26: 425-33.
26. Morimoto M, Numata K, Nozaki A etal. Novel lens culinaris agglutinin-reactive fraction of α-fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low α-fetoprotein concentrations. Int J Clin Oncol 2011 E pub Aug 26.
27. Kobayashi M, Hosaka T, Ikeda K etal. Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre-and postoperatively. Hepatol Res 2011 E pub Aug 26.
28. Komuta T, Mizukoshi E, Kita Y etal. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol 2007; 102: 1939-46.
29. Imai K, Takai K, Nishigaki Y etal. Insulin resistance raises the risk for recurrence of stage 1 hepatocellular carcinoma after curative ablation in hepatitis C virus-positive patients: a prospective, case series study. Hepatol Res 2010; 40: 376-82.
30. Huo TI, Wu JC, Lui WY etal. Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical treatment. Am J Gastroenterol 2004; 99: 1479-87.
31. Chen WT, Macatula TC, Lin CC, Lin CJ, Lin SM. Diabetes may not affect outcomes in hepatocellular carcinoma after radio-frequency ablation. Hepatogastroenterology 2011; 58: 551-7.
32. Wang WM, Xu Y, Yang XR, Wang YH, Sun HX, Fan J. Prognostic role of diabetes mellitus in hepatocellular carcinoma patients after curative treatments: a meta-analysis. Hepatobiliary Pancreat Dis Int 2011; 10: 346-55.
33. Ohki T, Tateishi R, Shiina S etal. Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. Gut 2009; 58: 839-44.
34. Tokushige K, Hashimoto E, Yatsuji S etal. Prospective study of hepatocellular carcinoma in non-alcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol 2101; 45: 960-7.
35. Goto T, Yoshida H, Tateishi R etal. Influence of serum HBVDNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation. Hepatol Int 2011 E pub Jan 25.
36. Yoshida H, Goto E, Sato T etal. Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol Int 2008; 2: 89-94.
37. Chan AC, Chok KS, Yuen WK, Chan RT, Lo CM, Fan ST. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg 2011; 146: 675-81.
38. Wong JS, Wong GL, Tsoi KK etal. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2011; 33: 1104-12.
39. Shirabe K, Takeishi K, Taketomi A, Uchiyama H, Kayashima H, Maehara Y. Improvement of long-term outcomes in hepatitis C virus antibody-positive patients with hepatocellular carcinoma after hepatectomy in the modern era. World J Surg 2011; 35: 1072-84.
40. Toyoda H, Kumada T, Kaneoka Y, Maeda A. Amino acid substitutions in the hepatitis C virus core region are associated with postoperative recurrence and survival of patients with genotype 1b-associated hepatocellular carcinoma. Ann Surg 2011; 254: 326-32.
41. Ikeda K, Arase Y, Saitoh S etal. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor- A prospective randomized study of hepatitis C virus-related cancer. Hepatology 2000; 32: 228-32.
42. Mazzaferro V, Romito R, Schiavo M etal. HCC Italian Task Force. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44: 1543-54.
43. Shiratori Y, Ito Y, Yokosuka O etal. Tokyo-Chiba Hepatitis Research Group. Antiviral therapy for cirrhotic hepatitis C: association with hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 18: 105-14.
44. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 2010; 17: 287-92.
45. Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol 2010; 52: 889-94.
46. Hagihara H, Nouso K, Kobayashi Y etal. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Clin Oncol 2011; 16: 210-20.
47. Kaibori M, Ishizaki M, Saito T, Matsui K, Kwon AH, Kamiyama Y. Risk factors and outcome of early recurrence after resection of small hepatocellular carcinomas. Am J Surg 2009; 198: 39-45.
48. Kuroda H, Ushio A, Miyamoto Y etal. Effects of branched-chain amino acid-enriched nutrient for patients with hepatocellular carcinoma following radiofrequency ablation: a one-year prospective trial. J Gastroenterol Hepatol 2010; 25: 1550-5.
49. Ishikawa T, Michitaka I, Kamimura H etal. Oral branched-chain amino acids administration improves impaired liver dysfunction after radiofrequency ablation therapy for hepatocellular carcinoma. Hepatogastroneterology 2009; 56: 1491-5.
50. Kawaguchi T, Izumi N, Charlton MR, Sata M. Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology 2011; 54: 1063-70.
51. Habu D, Shiomi S, Tamori A etal. Role of vitamin Ks in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 2004; 292: 358-61.
52. Mizuta T, Ozaki I, Eguchi Y etal. The effect of menatetteone, a vitamin K2 analogue, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment. Cancer 2006; 106: 867-72.
53. Kakizaki S, Sohara N, Sato K etal. Preventive effects of vitamin K on recurrence disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J Gastroenterol Hepatol 2007; 22: 518-22.
54. Hotta N, Ayada M, Sato K etal. Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma. Hepatogastroenterology 2007; 54: 2073-77.
55. Yoshida H, Shiratori Y, Kudo M etal. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology 2011; 54: 532-40.
56. Muto Y, Moriwaki H, Nonomiya M etal. Prevention of second primary tumors by an acyclic retionid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996; 13: 1561-7.
57. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999; 340: 1046-7.
58. Okita K, Matsui O, Kumada H etal. Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC): results of a phase II/III randomized placebo-controlled trial. Am Soc Clin Oncol 2011. ASCO Annual Meeting. Abstract No. 4024.
59. Hasegawa K, Takayama T, Ijichi M etal. Uracil-tegaful as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology 2006; 44: 891-95.
60. Prints C. Clinical trials of note. Sorafenib as adjuvant treatment for the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer 2009; 115: 4646.
61. Kudo M, Imanaka K, Chida N etal. Phase III study of sorafenib after transarterial chemoembolization in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47: 2117-27.